Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
← catalyst calendarNCT07220759 · readout in 266 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
330estimated
Sites
67
Countries
Argentina, Canada, Croatia +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-05 | actual | When the study began enrolling |
| Primary completion | 2027-05-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
- Type 2 Diabetes
Interventions
- Drug: Cagrilintide
- Drug: Placebo (matched to Cagrilintide)
Primary outcome
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to end of treatment (week 64)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed